Recent Updates
Recently added Catalysts
CELZ

AMENDMENT TO 8% PROMISSORY NOTE This Amendment to the 8% Promissory Note (this " Amendment "), dated effective

Key Takeaway: TO 8% PROMISSORY NOTE This Amendment to the 8% Promissory Note (this "Amendment"), dated effective April 11, 2018, is by, between, and among Creative Medical Technologies, Inc., a Nevada corporation (the "Borrower"), Creative Medical Health, Inc., a Delaware corporation (the

Full Press Release Details

TO 8% PROMISSORY NOTE
This Amendment to the
8% Promissory Note (this "Amendment"), dated effective April 11, 2018, is by, between, and among Creative Medical
Technologies, Inc., a Nevada corporation (the "Borrower"), Creative Medical Health, Inc., a Delaware corporation
(the "Holder"), and Creative Medical Technology Holdings, Inc. ("CELZ"). The Borrower, Holder,
and CELZ will be referred to individually as a "Party" and collectively as the "Parties."
Any capitalized terms not defined in this Amendment will have the meaning set forth in the 8% Promissory Note dated February 2,
2016 issued by the Borrower to the Holder (the "Note"), attached hereto as Exhibit A.
February 2, 2016, the Borrower issued to Holder the Note;
is not a party to the Note;
Note is not convertible into shares of Common Stock of CELZ; and
Parties hereto desire to make CELZ a party to the Note and to make the Note convertible into shares of Common Stock of the Borrower
through amending the Note to add a conversion feature and conversion notice.
consideration of the foregoing recitals, mutual covenants contained herein, and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties agree as set forth below.
Party. The Note is hereby amended so that, as amended, CELZ is a party to the Note.
Conversion. The Note is hereby amended so that, as amended, the following section is added:
after the issuance and until this Note is no longer outstanding, this Note shall be convertible, in whole or in part, into shares
of Common Stock of Creative Medical Technology Holdings, Inc., a Nevada corporation and parent of Maker ("CELZ")
at the option of the Payee, at any time and from time to time. The Payee shall effect conversions by delivering to the Maker and
CELZ a Notice of Conversion, the form of which is attached hereto as Annex A (a "Notice of Conversion"),
specifying therein the principal amount of this Note to be converted and the date on which such conversion shall be effected (such
date, the "Conversion Date"). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date
shall be the date that such Notice of Conversion is deemed delivered hereunder. No ink-original Notice of Conversion shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required. To
effect conversions hereunder, the Payee shall not be required physically to surrender this Note to the Maker unless the entire
principal amount of this Note, plus all accrued and unpaid interest thereon, has been so converted. Conversions hereunder shall
have the effect of lowering the outstanding principal amount of this Note in an amount equal to the applicable conversion. The
Payee and the Maker shall maintain records showing the principal amount(s) converted and the date of such conversion(s).
conversion price in effect on any Conversion Date shall be one hundred and twenty percent (120%) of the volume
weighted average price ("VWAP") from March 1, 2018 until March 30, 2018 (the "Conversion
of Conversion Shares issuable upon a conversion hereunder shall be determined by the quotient obtained by dividing (x) the outstanding
principal amount of this Note to be converted by (y) the Conversion Price.
shares or scrip representing fractional shares shall be issued upon the conversion of this Note. As to any fraction of a share
that the Payee would otherwise be entitled to purchase upon such conversion, the Maker shall at its election, either pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up
to the next whole share.
Notice. The Note is hereby amended so that, as amended, the following section is added:
NOTICE OF CONVERSION
The undersigned hereby
elects to convert principal under the 8% Promissory Note issued February 2, 2016 by Creative Medical Technologies, Inc., a Nevada
corporation (the "Maker"), to Creative Medical Health, Inc, a Delaware corporation (the "Payee"),
into shares of common stock (the "Common Stock") of Creative Medical Technology Holdings, Inc., a Nevada corporation
("CELZ"), according to the conditions hereof as of the date written below. If shares of Common Stock are to
be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect
thereto and is delivering herewith such certificates and opinions as reasonably requested by the Maker and CELZ in accordance therewith.
No fee will be charged to the holder for any conversion, except for such transfer taxes, if any.
Conversion calculations: Date to Effect Conversion: ________________ , 201__
Principal Amount of Note to be Converted: $ ________________________
Payment of Interest in Common Stock: __ yes __ no
If yes, $ ______of Interest Accrued on Account of Conversion at Issue.
Number of shares of Common Stock to be issued: ____________________
Signature: ___________________________________________________
Name: _________________________________
DWAC Instructions:
Broker Name, address, contact person, and telephone number:
___________________________________________________________
___________________________________________________________
___________________________________________________________
Broker DTC No: ________________________ _______________________
Account No: _________________________ _______________________
Other Changes. Except as amended hereby, the Note will continue to be, and will remain, in full force and effect. Except
as provided herein, this Amendment will not be deemed (i) to be a waiver of, or consent to, or a modification or amendment of,
any other term or condition of the Note or (ii) to prejudice any right or rights which the Parties may now have or may have in
the future under or in connection with the Note or any of the instruments or agreements referred to therein, as the same may be
amended, restated, supplemented or otherwise modified from time to time.
Binding on Successors. The Parties represent that they each have the authority to enter into this Amendment. This Amendment
will be binding on, and will inure to the benefit of, the Parties to it and their respective heirs, legal representatives, successors,
Law and Venue. This Amendment and the rights and duties of the Parties hereto will be construed and determined in accordance
with the terms of the Note.
by Reference. The terms of the Note, except as amended by this Amendment, are incorporated herein by reference and will
form a part of this Amendment as if set forth herein in their entirety.
Facsimile Execution. This Amendment may be executed in any number of counterparts and all such counterparts taken together
will be deemed to constitute one instrument. Delivery of an executed counterpart of this Amendment by facsimile or email will be
equally as effective as delivery of a manually executed counterpart of this Amendment.
[Signature Page to Follow]
each of the undersigned has executed this Amendment the respective day and year set forth below:
MAKER: Creative Medical Technologies, Inc.
Date: April 13, 2018 By /s/ Timothy Warbington
Timothy Warbington, CEO
PAYEE: Creative Medical Health, Inc.
Date: April 13, 2018 By /s/ Timothy Warbington
Timothy Warbington, CEO
CELZ: Creative Medical Technology Holdings, Inc.
Date: April 13, 2018 By /s/ Timothy Warbington
Timothy Warbington, CEO
8% Promissory Note dated February 2, 2016
Last updated: Apr 11, 2018